Author: John Meady

Finance

Utilities Active Runners: Companhia Energetica Minas Gerais (ADR) (NYSE:CIG), AES Corp (NYSE:AES), Exelon Corporation (NYSE:EXC), PG&E Corporation (NYSE:PCG)

Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) had its stock coverage assumed at Goldman Sachs Group Inc (NYSE:GS). The firm assigned buy rating on the stock. That positive rating of the stock came hot on the heels of the upgrade from Zacks, where analysts at Zacks assigned neutral on the stock from underperform. Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) stock performance was 0.89% in last session … Continue reading Utilities Active Runners: Companhia Energetica Minas Gerais (ADR) (NYSE:CIG), AES Corp (NYSE:AES), Exelon Corporation (NYSE:EXC), PG&E Corporation (NYSE:PCG)

John Meady
BBRY NASDAQ BBRY Blackberry
Diversified Tech, Internet, Mobile

BlackBerry’s Q4 Loss Narrower than Expected

BlackBerry (BBRY, BB.TO) reported a Q4 adjusted loss of $0.08 per share, better than expectations of a loss of $0.54 per share, if comparable. Revenue was $976 million, down 64% from $2.7 billion in the year ago quarter, and below the analyst consensus of $1.2 billion on Capital IQ. During Q4, the company recognized hardware revenue on approximately 1.3 million BlackBerry smartphones compared to approximately … Continue reading BlackBerry’s Q4 Loss Narrower than Expected

John Meady
Finance

Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)

U.S. health regulators on Friday approved a Celgene Corporation (NASDAQ:CELG) drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling. Celgene Corporation (NASDAQ:CELG) stock performance was -3.74% in last session and finished the day at $144.40. Traded volume was 9.50million shares in the last session and the average volume of the stock remained … Continue reading Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)

John Meady
Diversified Tech

NovaBay Pharmaceuticals Tumbles 9% in After Hours; Guess (GES) Down as Well

NovaBay Pharmaceuticals (NYSEMKT:NBY) is lower in late trading after the clinical-stage biopharmaceutical company said late Wednesday that it intends to offer shares of its common stock and warrants in an underwritten public offering. Shares are down 8.73% at $1.15, with a 52-week range of $0.76 – $2.03. The company intends to use the net proceeds from this offering for working capital and general corporate purposes, … Continue reading NovaBay Pharmaceuticals Tumbles 9% in After Hours; Guess (GES) Down as Well

John Meady
Finance

NASDAQ Gainers: Ariad Pharmaceuticals (NASDAQ:ARIA), Yandex NV (NASDAQ:YNDX), GT Advanced Technologies (NASDAQ:GTAT), Oculus Innovative Sciences (NASDAQ:OCLS)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading NASDAQ Gainers: Ariad Pharmaceuticals (NASDAQ:ARIA), Yandex NV (NASDAQ:YNDX), GT Advanced Technologies (NASDAQ:GTAT), Oculus Innovative Sciences (NASDAQ:OCLS)

John Meady
Diversified Tech

Healthcare Stocks to Watch: TrovaGene (NASDAQ:TROV), AstraZeneca plc (ADR) (NYSE:AZN), Life Partners Holdings Inc. (NASDAQ:LPHI), Alliance HealthCare Services Inc. (NASDAQ:AIQ)

TrovaGene (NASDAQ:TROV) reported that for Q4, it narrowed its loss year over year, beating Street estimates, while revenue fell versus the prior year period and fell short of analysts’ expectations. The development-stage molecular diagnostic company reported a Q4 net loss of $1 million, or $0.05 per share, compared with the prior-year period’s net loss of $6.3 million, or $0.43 per share. Revenue was $47,000 down … Continue reading Healthcare Stocks to Watch: TrovaGene (NASDAQ:TROV), AstraZeneca plc (ADR) (NYSE:AZN), Life Partners Holdings Inc. (NASDAQ:LPHI), Alliance HealthCare Services Inc. (NASDAQ:AIQ)

John Meady